A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection
Not Applicable
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002453
- Lead Sponsor
- Gilead Sciences
- Brief Summary
This study allows patients who need a new anti-HIV treatment to take tenofovir disoproxil fumarate (tenofovir DF), an experimental drug. This study also looks at any side effects the drug causes.
- Detailed Description
HIV-1-infected patients who are currently receiving stable antiretroviral therapy add tenofovir DF to their regimen. Study participation lasts for approximately 48 weeks. Interested patients should contact their physicians.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Tenofovir Disoproxil Fumarate in HIV-1 treatment?
How does Tenofovir Disoproxil Fumarate compare to standard-of-care nucleoside reverse transcriptase inhibitors in HIV management?
Which biomarkers correlate with virologic response to Tenofovir DF in HIV-infected patients on combination antiretroviral therapy?
What adverse events are associated with Tenofovir DF compassionate use in HIV treatment regimens?
How do combination therapies involving Tenofovir DF impact HIV-1 viral load suppression compared to monotherapy or other NRTI-based regimens?
Trial Locations
- Locations (1)
Tenofovir Coordinating Center
🇺🇸Foster City, California, United States
Tenofovir Coordinating Center🇺🇸Foster City, California, United States